This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 ETF Picks for October
by Sanghamitra Saha
A few ETF choices for the month of October.
Here's Why Bluebird Bio (BLUE) Stock Is Falling Today
by Ryan McQueeney
Shares of Bluebird Bio (BLUE), a major player in the emerging gene therapy and CAR-T research markets, slumped more than 6% in morning trading Monday after receiving a key analyst downgrade.
How Will Trump's Proposed Tax Reform Impact Drug Companies?
by Zacks Equity Research
Donald Trump has proposed new tax reforms for individuals and corporates. Let's see how the reforms, if passed, will impact pharma companies.
Gilead (GILD) Gets Approval for HCV Drug Sovaldi in China
by Zacks Equity Research
Gilead Sciences' (GILD) blockbuster hepatitis C virus (HCV) infection drug, Sovaldi is now approved in China also.
Kite Pharma Triples So Far in 2017: What's Driving the Rally?
by Zacks Equity Research
Kite Pharma's (KITE) shares have surged 300% so far this year riding on the progress of its CAR-T therapy candidate and a favorable buyout offer from Gilead.
Gilead's (GILD) Epclusa Receives Label Expansion in Canada
by Zacks Equity Research
Gilead Sciences Inc. (GILD) announced that Health Canada has approved a label update of hepatitis C virus drug, Epclusa.
Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval
by Zacks Equity Research
Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.
3 Pharma/Biotech Sector Bargains for a Healthy Portfolio
by Zacks Equity Research
The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.
Implied Volatility Surging for Kite Pharma (KITE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Kite Pharma (KITE) stock based on the movements in the options market lately.
Gilead Buys Kite, the Future of CAR-T, and A Visit to the New Whole Foods
by Ryan McQueeney
On today's episode of the Zacks Friday Finish Line, Content Writer Ryan McQueeney and Editor Maddy Johnson take on this week's biggest stories, including Gilead's acquisition of Kite Pharma, the future of the CAR-T therapy industry, and Amazon's changes to Whole Foods stores.
4 Biotech Stocks That More Than Doubled This Year
by Zacks Equity Research
The biotech sector has been witnessing an uptrend this year with impressive performance in both the quarters. Shares of quite a few companies have more than doubled so far this year riding this trend.
5 Top Performing Stocks of the Top ETF of August
by Sweta Killa
Inside the top performing ETF of August and its top stocks.
Novartis (NVS) CAR-T Therapy Kymriah Receives FDA Approval
by Zacks Equity Research
Novartis AG (NVS) gets a major boost as the FDA approved its breakthrough gene transfer treatment, Kymriah for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL).
Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap
by Ryan McQueeney
The cancer treatment industry is celebrating a massive victory on Wednesday, as Novartis (NVS) received approval for its innovative new lymphoblastic leukemia treatment, making it the first approved CAR-T therapy in the world.
Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal
by Zacks Equity Research
Gilead's (GILD) $11.8 billion deal to buy Kite Pharma KITE) has made two other leading independent CAR-T developers, Juno and Bluebird Bio hot takeover targets.
The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG
Indecision Won't Kill You, But It Will Take Your Money
by Kevin Cook
The pitfalls and powers of decision-making for traders and investors could be a model for everyone else.
Gilead to Fly High with Kite Pharma Acquisition for $11.9B
by Zacks Equity Research
Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy.
Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition
by Ryan McQueeney
Shares of Juno Therapeutics (JUNO) continued to soar on Tuesday. The stock has now gained nearly 40% since the announcement that fellow CAR-T cancer therapy designer Kite Pharma (KITE) is being acquired by biotech behemoth Gilead Sciences (GILD).
Why Did Kite Pharma (KITE) Stock Skyrocket Today?
by Benjamin Rains
Shares of cancer treatment drug maker Kite Pharma (KITE) soared on Monday morning after Gilead Sciences (GILD) officially announced it would purchase the company for a substantial premium.
Kite Pharma at New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Kite Pharma (KITE) shares hit a new 52-week high as the company's CAR-T therapy with axicabtagene ciloleucel nears an FDA nod. It has also filed regulatory application for the candidate in the EU.
Kite Pharma (KITE) Q2 Loss Narrower than Expected, Shares Up
by Zacks Equity Research
Kite Pharma, Inc. (KITE) reported narrower-than-expected loss in the second quarter of 2017 and beat estimates for sales. Shares of the biotech company rose 5.8% on Tuesday.
Kite Pharma (KITE) Q2 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Kite Pharma (KITE) reported narrower than expected loss in Q2 while sales beat expectations.
Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More
by Zacks Equity Research
A look at the pharma/biotech companies that are set to report second-quarter results on Aug 8.
What's in the Cards for Kite Pharma (KITE) in Q2 Earnings
by Zacks Equity Research
With no approved products in its portfolio, investor focus will primarily be on Kite Pharma, Inc.'s (KITE) cash burn and pipeline updates.